Cargando…
Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML
Despite advances in the treatment of acute myeloid leukemia (AML), prognosis of AML patients is still dismal and better treatment options are required. B-cell Lymphoma 2 (BCL-2) homology domain 3 (BH3)-mimetics are emerging as a novel class of apoptosis-inducing agents that are currently being teste...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892884/ https://www.ncbi.nlm.nih.gov/pubmed/31801941 http://dx.doi.org/10.1038/s41419-019-2156-2 |